



# Verona Pharma

31 October 2017

## Verona Pharma to Announce Operational Update and Financial Results for the Third Quarter Ended September 30, 2017

LONDON, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that it will report its financial results for the three months ended September 30, 2017 on Tuesday, November 7, 2017.

Verona Pharma will host an investment community conference call at 8:00 a.m. Eastern Standard Time (1:00 pm Greenwich Mean Time) on November 7, 2017 to discuss the third quarter financial results and provide a clinical development update.

Analysts and investors may participate in the conference call by utilizing the conference ID: 1550110 and dialing the following numbers:

- (877)280-1254 or (646)254-3388 for callers in the United States
- 0800 279 5736 or 44(0)20 3427 1901 for callers in the United Kingdom
- 0800 589 2673 or 49(0)69 2222 10619 for calls in Germany

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors" page of Verona Pharma's website at [www.veronapharma.com](http://www.veronapharma.com) and clicking on the webcast link.

A webcast replay of the conference call [audio] will be available on the "Investors" page of Verona Pharma's website at [www.veronapharma.com](http://www.veronapharma.com).

### About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo, and has shown clinically meaningful and statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.

### For further information, please contact:

Verona Pharma plc  
Jan-Anders Karlsson, Chief Executive Officer

Tel: +44 (0)20 3283 4200  
[info@veronapharma.com](mailto:info@veronapharma.com)

Stifel Nicolaus Europe Limited (Nominated Adviser and UK Broker)

Tel: +44 (0) 20 7710 7600

Stewart Wallace / Jonathan Senior / Ben Maddison

[SNELVeronaPharma@stifel.com](mailto:SNELVeronaPharma@stifel.com)

FTI Consulting (UK Media and Investor enquiries)  
Simon Conway / Natalie Garland-Collins

Tel: +44 (0)20 3727 1000  
[veronapharma@fticonsulting.com](mailto:veronapharma@fticonsulting.com)

ICR, Inc. (US Media and Investor enquiries)

James Heins

Stephanie Carrington

Tel: +1 203-682-8251

James.Heins@icrinc.com

Tel. +1 646-277-1282

Stephanie.Carrington@icrinc.com

Source: Verona Pharma plc

---

For further information please contact: Verona Pharma plc

**Verona Pharma plc**

Jan-Anders Karlsson, CEO

Victoria Stewart, Director of Communications

Tel: +44 (0)20 3283 4200

info@veronapharma.com

**N+1 Singer (Nominated Adviser and UK Broker)**

Aubrey Powell /Jen Boorer /Iqra Amin (Corporate Finance)

Brough Ransom /Mia Gardner (Corporate Broking)

Tel: +44 (0)20 3283 4200

**Optimum Strategic Communications**

(European Media and Investor enquiries)

Mary Clark, Annemarieke Ezendam

Hollie Vile

Tel: +44 (0) 203 922 0891

verona@optimumcomms.com

**Westwicke, an ICR Company (Investor enquiries)**

Stephanie Carrington

Tel. +1 646-277-1282

Stephanie.Carrington@icrinc.com

---

**About Verona Pharma plc**

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

**Forward Looking Statements**

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or

achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.